Caveolin-1 as a potential high-risk prostate cancer biomarker

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 831-841

  Gumulec, Jaromir ^a,b   Sochor, Jiri ^b,c   Hlavna, Marian ^a   Sztalmachova, Marketa ^a,b   Krizkova, Sona ^b,c   Babula, Petr ^b,c   Hrabec, Roman ^d   Rovny, Arne ^d   Adam, Vojtech ^b,c   Eckschlager, Tomas ^e   Kizek, Rene ^b,c   Masarik, Michal ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^c BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Electrochemistry; Immunodetection; Molecular biology techniques; Polymerase chain reaction; Prognostic marker; Prostate cancer; Tumour marker

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; CAVEOLIN 1; CHROMIUM PEROXIDE; FREE RADICAL; GLUTATHIONE; METALLOTHIONEIN; N,N' DIPHENYL 1,4 PHENYLENEDIAMINE; PEROXIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FERRIC REDUCING ANTIOXIDANT POWER; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; TROLOX EQUIVALENT ANTIOXIDANT CAPACITY;

AGED; ANTIOXIDANTS; BIPHENYL COMPOUNDS; CAVEOLIN 1; CHROMANS; CHROMIUM COMPOUNDS; FREE RADICALS; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDES; PICRATES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856292514     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1587     Document Type: Article

References (75)

1. Gannot G, Tangrea MA, Richardson AM, et al: Layered expression scanning: multiplex molecular analysis of diverse life science platforms. Clin Chim Acta 376: 9-16, 2007. (Pubitemid 44895543)
2. Bensalah K, Montorsi F and Shariat SF: Challenges of cancer biomarker profiling. Eur Urol 52: 1601-1609, 2007. (Pubitemid 350052431)
3. Duffy MJ: PSA as a marker for prostate cancer: a critical review. Ann Clin Biochem 33: 511-519, 1996.
4. Matsumoto K, Irie A, Satoh T, Kuruma H, Arakawa T and Baba S: Occupational bladder cancer: from cohort study to biologic molecular marker. Med Sci Monitor 11: RA311-RA315, 2005. (Pubitemid 41482743)
5. Sargent DJ, Conley BA, Allegro C and Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23: 2020-2027, 2005. (Pubitemid 46211382)
6. Sarrazin S, Adam E, Lyon M, et al: Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765: 25-37, 2006. (Pubitemid 41752939)
7. Tuxen MK: Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol 16: 49-68, 2001.
8. Zehentner BK and Carter D: Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 37: 249-257, 2004. (Pubitemid 38314877)
9. Barry MJ: Prostate-specificy-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344: 1373-1377, 2001.
10. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
11. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
12. Schmid HP, McNeal JE and Stamey TA: Observations on the doubling time of prostate-cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031-2040, 1993. (Pubitemid 23068553)
13. Palade GE: Fine structure of blood capillaries. J Appl Phys 24: 1424-1424, 1953.
14. Patra SK and Bettuzzi S: Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: A role for raft proteins in cell transformation and cancer progression (Review). Oncol Rep 17: 1279-1290, 2007.
15. Gould ML, Williams G and Nicholson HD: Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 70: 1609-1621, 2010.
16. Couet J, Belanger MM, Roussel E and Drolet MC: Cell biology of caveolae and caveolin. Adv Drug Deliv Rev 49: 223-235, 2001. (Pubitemid 32718685)
17. Frank PG, Pavlides S and Lisanti MP: Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res 335: 41-47, 2009.
18. Zheng YZ and Foster LJ: Biochemical and proteomic approaches for the study of membrane microdomains. J Proteomics 72: 12-22, 2009.
19. Volonte D, Galbiati F and Lisanti MP: Visualization of caveolin-1, a caveolar marker protein, in living cells using green fluorescent protein (GFP) chimeras. The subcellular distribution of caveolin-1 is modulated by cell-cell contact. FEBS Lett 445: 431-439, 1999. (Pubitemid 29117257)
20. UniProt knowledgebase for Q03135 (Cav1-Human). http://www.uniprot.org/ uniprot/Q03135.
21. Shatz M and Liscovitch M: Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 84: 177-189, 2008. (Pubitemid 351323417)
22. Burgermeister E, Liscovitch M, Rocken C, Schmid RM and Ebert MPA: Caveats of caveolin-1 in cancer progression. Cancer Lett 268: 187-201, 2008.
23. Ando T, Ishiguro H, Kimura M, et al: The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep 18: 601-609, 2007.
24. Zhang Q, Furukawa K, Chew HH, et al: Down-regulation of caveolin-1 in mouse Lewis lung cancer P29 is a causal factor for the malignant properties in a high-metastatic subline. Oncol Rep 16: 289-294, 2006.
25. Williams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494-C506, 2005. (Pubitemid 40229478)
26. Conde MC, Ramirez-Lorca R, Lopez-Jamar JME, et al: Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep 16: 353-359, 2006.
27. Dasari A, Bartholomew JN, Volonte D and Galbiati F: Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66: 10805-10814, 2006. (Pubitemid 44876976)
28. Chen DB, Li SM, Qian XX, Moon CS and Zheng J: Tyrosine phosphorylation of caveolin 1 by oxidative stress is reversible and dependent on the c-src tyrosine kinase but not mitogen-activated protein kinase pathways in placental artery endothelial cells. Biol Reprod 73: 761-772, 2005.
29. Krizkova S, Adam V, Petrlova J, et al: A suggestion of electrochemical biosensor for study of platinum(II)-DNA interactions. Electroanalysis 19: 331-338, 2007.
30. Popiela TJ, Rudnicka-Sosin L, Dutsch-Wicherek M, et al: The metallothionein and RCAS1 expression analysis in breast cancer and adjacent tissue regarding the immune cells presence and their activity. Neuro Endocrinol Lett 27: 786-794, 2006. (Pubitemid 46138640)
31. Zelena J, Potesil D, Vacek J, et al: Metallothionein as a prognostic marker of tumor disease. Klin Onkol 17: 190-195, 2004. (Pubitemid 40066099)
32. Ebert MPA, Günther T, Hoffmann J, et al: Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res 60: 1995-2001, 2000. (Pubitemid 30207662)
33. Kasahara K, Fujiwara Y, Nishio K, et al: Metallothionein content correlates with the sensitivity of human small cell lung cancer lines to cisplatin. Cancer Res 51: 3237-3242, 1991.
34. Theocharis SE, Margeli AP, Klijanienko JT and Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology 45: 103-118, 2004. (Pubitemid 39120406)
35. Adam V, Baloun J, Fabrik I, Trnkova L and Kizek R: An electrochemical detection of metallothioneins at the zeptomole level in nanolitre volumes. Sensors 8: 2293-2305, 2008.
36. Adam V, Blastik O, Krizkova S, et al: Application of the Brdicka reaction in determination of metallothionein in patients with tumours. Chem Listy 102: 51-58, 2008.
37. Fabrik I, Krizkova S, Huska D, et al: Employment of electrochemical techniques for metallothionein determination in tumour cell lines and patients with a tumor disease. Electroanalysis 20: 1521-1532, 2008.
38. Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci 10: 360-375, 2009.
39. Adam V, Fabrik I, Eckschlager T, Stiborova M, Trnkova L and Kizek R: Vertebrate metallothioneins as target molecules for analytical techniques. TrAC-Trends Anal Chem 29: 409-418, 2010.
40. Adam V, Petrlova J, Wang J, Eckschlager T, Trnkova L and Kizek R: Zeptomole electrochemical detection of metallothioneins. PLoS One 5: e11441, 2010.
41. Ryvolova M, Krizkova S, Adam V, et al: Analytical methods for metallothionein detection. Curr Anal Chem 7: 243-261, 2011.
42. Kizek R, Trnkova L and Palecek E: Determination of metallothionein at the femtomole level by constant current stripping chronopotentiometry. Anal Chem 73: 4801-4807, 2001. (Pubitemid 32980100)
43. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003. (Pubitemid 37487869)
44. Jin R, Huang J, Tan PH and Bay BH: Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 10: 74-79, 2004. (Pubitemid 38915598)
45. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988.
46. Theocharis S, Karkantaris C, Philipides T, et al: Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 40: 143-151, 2002. (Pubitemid 34122116)
47. Kuefer R, Varambally S, Zhou M, et al: α-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 161: 841-848, 2002. (Pubitemid 34988371)
48. Luo J, Zha S, Gage WR, et al: α-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220-2226, 2002. (Pubitemid 34411693)
49. Xu J, Stolk JA, Zhang X, et al: Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60: 1677-1682, 2000. (Pubitemid 30183441)
50. Evans AJ: α-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 56: 892, 2003.
51. Buttke TM and Sandstrom PA: Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7-10, 1994.
52. Droge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
53. Valko M, Rhodes CJ, Moncol J, Izakovic M and Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40, 2006. (Pubitemid 43227479)
54. Potesil D, Petrlova J, Adam V, et al: Simultaneous femtomole determination of cysteine, reduced and oxidized glutathione, and phytochelatin in maize (Zea mays L.) kernels using high-performance liquid chromatography with electrochemical detection. J Chromatogr A 1084: 134-144, 2005. (Pubitemid 40966920)
55. Petrlova J, Mikelova R, Stejskal K, et al: Simultaneous determination of eight biologically active thiol compounds using gradient elution-liquid chromatography with Coul-Array detection. J Sep Sci 29: 1166-1173, 2006. (Pubitemid 43871372)
56. Sochor J, Ryvolova M, Krystofova O, et al: Fully automated spectrometric protocols for determination of antioxidant activity: advantages and disadvantages. Molecules 15: 8618-8640, 2010.
57. Laemmli UK: Cleavage of structural proteins during assembly of head of bacteriophage-T4. Nature 227: 680-685, 1970.
58. Merril CR, Dunau ML and Goldman D: A rapid sensitive silver stain for polypeptides in polyacrylamide gels. Anal Biochem 110: 201-207, 1981.
59. Krizkova S, Ryvolova M, Gumulec J, et al: Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker. Electrophoresis 32: 1952-1961, 2011.
60. Volonte D, Galbiati F, Pestell RG and Lisanti MP: Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase - Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J Biol Chem 276: 8094-8103, 2001.
61. Duplancic D, Kukoc-Modun L, Modun D and Radic N: Simple and rapid method for the determination of uric acid-independent antioxidant capacity. Molecules 16: 7058-7067, 2011.
62. Bartosz G: Non-enzymatic antioxidant capacity assays: limitations of use in biomedicine. Free Radic Res 44: 711-720, 2010.
63. Prior RL and Cao GH: In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic Biol Med 27: 1173-1181, 1999. (Pubitemid 30001476)
64. Tahir SA, Ren CZ, Timme TL, et al: Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9: 3653-3659, 2003. (Pubitemid 37169231)
65. Nasu Y, Timme TL, Yang G, et al: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4: 1062-1064, 1998. (Pubitemid 28417340)
66. Yang G, Truong LD, Wheeler TM and Thompson TC: Caveolin-l expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59: 5719-5723, 1999.
67. Tahir SA, Frolov A, Hayes TG, et al: Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 12: 4872-4875, 2006. (Pubitemid 44338573)
68. Thompson TC, Tahir SA, Li L, et al: The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13: 6-11, 2010.
69. Watanabe M, Yang G, Cao GW, et al: Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 7: 1446-1455, 2009.
70. Tahir SA, Yang G, Ebara S, et al: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001. (Pubitemid 32720945)
71. Yang G, Truong LD, Timme TL, et al: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998. (Pubitemid 28369170)
72. Thompson TC, Timme TL, Li L and Goltsov A: Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 4: 233-237, 1999. (Pubitemid 29424486)
73. Li LK, Yang G, Ebara S, et al: Caveolin-1 mediates testosterone- stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386-4392, 2001. (Pubitemid 32685764)
74. Mouraviev V, Li LK, Tahir SA, et al: The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168: 1589-1596, 2002. (Pubitemid 35034195)
75. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI and Shariat SF: Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67: 614-622, 2007. (Pubitemid 46685281)